Shahina Mukadam, Independent Market Expert is of the view that one may prefer Larsen and Toubro, State Bank of India and Aurobindo Pharma.
"As we have seen while there could be some order book could take some more time to really pick up momentum, but I think the cost optimisation that the company has put in place should enable it to improves its margin."
"Second one would be another long-term relatively stable stock like State Bank of India (SBI). There again, we are likely to see a decent of numbers; treasury gains should boost the profitability for the bank in this quarter. Also I think going forward with interest rates coming down, it will be able to maintain its market share. That is one bank which should continue to do well in the PSU space."
"I would prefer Aurobindo Pharma. I personally hold the stock. Here it is a combination of the potential over the next two to three years where they have got a statin product which will be a relative less competition product that will be launched in a US market. That should drive revenues in the next year. As well as valuations are there in its advantage, so I think Aurobindo Pharma could be another stock that one could look at," she added.